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Abstract
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by experimental HIV-1
vaccines. When these antibodies do occur, it is important to be able to isolate and characterize them to provide clues for
vaccine design. CAP206 is a South African subtype C HIV-1-infected individual previously shown to have broadly
neutralizing plasma antibodies targeting the envelope gp41 distal membrane proximal external region (MPER). We have
now used a fluoresceinated peptide tetramer antigen with specific cell sorting to isolate a human neutralizing monoclonal
antibody (mAb) against the HIV-1 envelope gp41 MPER. The isolated recombinant mAb, CAP206-CH12, utilized a portion of
the distal MPER (HXB2 amino acid residues, 673–680) and neutralized a subset of HIV-1 pseudoviruses sensitive to CAP206
plasma antibodies. Interestingly, this mAb was polyreactive and used the same germ-line variable heavy (VH1-69) and
variable kappa light chain (VK3-20) gene families as the prototype broadly neutralizing anti-MPER mAb, 4E10 (residues 672–
680). These data indicate that there are multiple immunogenic targets in the C-terminus of the MPER of HIV-1 gp41
envelope and suggests that gp41 neutralizing epitopes may interact with a restricted set of naive B cells during HIV-1
infection.
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Introduction
The isolation of new anti-HIV-1 envelope neutralizing human
monoclonal antibodies (mAbs) is a high priority since they may
identify potential targets for vaccine design. Until recently only a
handful of such mAbs were available, and these were isolated
either through traditional EBV-transformation or phage-display
libraries [1,2,3,4]. Newer state-of-the art technologies utilizing
single cell sorting of antigen-specific memory B cells together with
PCR amplification of immunoglobulin gene (Ig) fragments have
produced additional antibodies including VRC01, a potent new
anti-CD4 binding site (CD4bs) mAb [5,6]. Furthermore, high-
throughput neutralization screening of short-term memory B cell
cultures yielded PG9 and PG16 mAbs, which are broadly cross-
reactive and define a new target on the gp120 envelope
glycoprotein [7].
The membrane proximal external region (MPER) in gp41
represents an important target for anti-HIV-1 neutralizing
antibodies [8]. This highly conserved stretch of ,23 amino acids
in gp41 proximal to the viral membrane is required for viral
infectivity. The broadly neutralizing antibody 2F5 binds amino
acid residues 663–667 at the MPER N-terminus with the
tripeptide motif 664DKW666 essential for its recognition [9].
MPER mAb 4E10 shows greater breadth and binds residues
within the C-terminus with amino acids W672,F 673 and W680
critical for binding [9]. Both antibodies have long CDRH3 regions
with hydrophobic CDRH3 loops that confer lipid polyreactivity
[10]. This enables the antibodies to bind first to virion lipids,
which optimizes binding to the gp41 intermediate epitope that is
transiently exposed during virion induced cell fusion [11]. A third,
less potent mAb Z13e1, overlaps the 4E10 epitope spanning
residues 668–677 and makes contact with N671 and D674 [12].
While anti-MPER antibodies have been detected in plasma of
approximately one third of HIV-infected individuals, using
chimeric viruses with HIV-1 MPER grafted into a SIV or an
HIV-2 envelope glycoprotein, antibodies with 2F5 and 4E10
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antibodies targeting other epitopes within the MPER is largely
unknown.
We recently described anti-MPER antibodies in a chronically
infected subtype C infected individual (CAP206) that were
responsible for plasma neutralization breadth, and were targeted
to the distal MPER centered around D674 [15]. Here we describe
isolation of a novel anti-MPER neutralizing mAb from this
individual, CAP206-CH12; through the amplification of Ig gene
fragments from single memory B cells sorted using a fluorescently-
labeled MPER-peptide tetramer. This mAb overlapped the 4E10
and Z13e1 epitopes and neutralized a subset of viruses sensitive to
plasma antibodies. CAP206-CH12 used the same VH and Vk Ig
gene families as the 4E10 mAb and its CDRH3 sequence showed
strong similarities with that of Z13e1 as a result of shared J gene
usage [16]. These data suggest the possibility of convergent
evolution among HIV-1 gp41 MPER mAbs.
Results
CAP206 Plasma Reactivity and Labeling of MPER-Reactive
Memory B Cells
We have previously identified an HIV-1-infected individual
from the CAPRISA 002 acute infection cohort in Durban, South
Africa who developed broadly cross-reactive neutralizing antibod-
ies targeting the MPER [15]. This was shown by depleting
neutralizing activity from plasma using MPR.03 peptide-coated
beads. Of the 44 viruses tested, 50% were neutralized by CAP206
plasma of which 68% were confirmed to be neutralized via anti-
MPER antibodies [15].
The ability to deplete specific antibodies from the plasma of
CAP206 using an MPER peptide suggested that it may be possible
to label and sort memory B cells producing these antibodies. We
therefore designed a tetramer using MPR.03 monomer peptide
which was biotinylated and reacted with streptavidin to yield a
tetramer with 4 MPER epitopes for B cell surface Ig cross-linking
[17]. To decrease the overall labeling background, MPR.03
tetramers were labeled with either AF647 or PacBlue and used to
stain PBMC from CAP206 collected at 28 months post-infection.
Memory B cells (CD19
+, CD27
+) that were dual stained with both
MPR.03-AF647 and MPR.03-PacBlue were sorted into individual
wells of a 96 well plate (Figure 1A). The frequency of tetramer-
specific B cells was approximately 0.4% of memory B cells. Given
that memory B cells constituted ,1–2% of this sample we
estimated that the peptide-binding B cells represented less than 1
in 10,000 of total PBMC.
Isolation of CAP206-CH12, an HIV-1 MPER-Reactive MAb
Single cell PCR amplification and transient expression of Ig
genes of sorted B cells yielded an IgG1 mAb, CAP206-CH12 that
reacted strongly with the MPR.03 peptide but not with a
scrambled version in an ELISA (Figure 1B). It also bound the
MPER656 peptide which differed from MPR.03 at position 674
(N in MPER656 and D in MPR.03). It did not bind to a peptide
from the gp41 immunodominant region (ID, SP400) or peptides
that bound the 2F5 and 4E10. This mAb also did not react with
trimeric MN gp41 protein, JR-FL gp140 or the group M
consensus Env protein (ConS gp140). CAP206-CH12 also failed
to recognize these proteins in Western blots done under reducing
and non-reducing conditions (Figure 1C), despite JR-FL and ConS
sharing an almost identical sequence to the MPR.03 peptide (JR-
FL differs by a single amino acid, 677K). In contrast, CAP206-
CH12 bound well to the autologous gp140 protein by ELISA and
Western blot.
Remarkably, mAb CAP206-CH12 used the same heavy and
light chain gene families as the 4E10 mAb, namely VH1-69 and
VK3-20 and the same JH family as another anti-MPER mAb,
Z13e1 (Table 1). It had the shortest CDRH3 (17 amino acids) and
the longest CDRL3 (11 amino acids) of the three antibodies. The
mutation rate in the heavy chain was similar to 4E10 but it had the
highest number of light chain mutations. The CDRH3 of
CAP206-CH12 had four tyrosines similar to Z13e1 as a result of
the shared J6*03 allele. However, all 3 antibodies were genetically
distinct (see Figure S1 for amino acid alignments and nucleotide
sequences).
In addition to CAP206-CH12, a second functional antibody
with a VH3-7 heavy chain was isolated but it failed to bind the
MPR.03 peptide. A further four heavy chain genes were
sequenced, but these were either non-functional or paired light
chains could not be amplified. One of these also used VH3-7 and
unlikely to be specific. However, the other three used the VH1-69
heavy chain genes with CDRH3 regions between 11–18 amino
acids, similar to CAP206, suggesting that additional MPER-
specific mAbs exist. Attempts to repair these or to pair them with
the CAP206-CH12 light chain were unsuccessful.
Characterization of Binding Sites and Affinity of
CAP206-CH12
In surface plasmon resonance measurements, CAP206-CH12
mAb bound to MPR.03 peptide with a Kd of 7.3 nM (Figure 2A)
which was comparable to that of 4E10. Alanine scanning studies
showed that the CAP206-CH12 binding epitope spanned the
672WF(N/D)IT676 motif, which overlapped with the 4E10 [9]
(Figure S2) and Z13e1 epitopes [12]. With the exception of T676A
(,30% reduced), all other substitutions reduced CAP206-CH12
binding by .50% relative to the wild type peptide. Although
CAP206-CH12 epitope included two critical residues of the 4E10
epitope, W672 and F673 [9], single alanine substitution of either
W672 or F673 had a more drastic effect on 4E10 binding (,20%
binding) than on CAP206-CH12 (30–40% binding) (Figure S2). A
critical residue for Z13e1 binding and neutralization, N671 and
residues N-terminus to this (S668LW670), did not play a role in
CAP206-CH12 binding (Figure S2). Thus, the core epitope of
CAP206-CH12 was slightly narrower and included C-terminus
residues of gp41 MPER that overlapped with the epitope of 4E10.
Previously, 2F5 and 4E10 mAbs were shown to bind strongly
with exceptionally slow off-rates to trimeric 92UG gp41-inter, a
protein that mimics the pre-hairpin intermediate state of gp41
[18]. CAP206-CH12 bound to gp41-inter suggesting that it
recognizes the MPER presented in the pre-hairpin conformation
of gp41 (Figure 2C). However, when compared to 4E10 binding
(Kd=1.6 nM; koff=1.5610
25 s
21, 25), CAP206-CH12 binding
to gp41-inter was considerably weaker (Kd=21.4 nM) and
displayed about 10-fold faster off-rates (koff=2.2610
24 s
21). This
may explain the lower neutralization potency of CAP206-CH12
when compared to that of 4E10.
The putative CAP206-CH12 germline antibody or reverted
unmutated ancestor, CAP206-CH12_RUA also bound to
MPR.03 peptide but with a binding Kd of 120 nM (Figure 2B),
which was about 15-fold weaker than that of CAP206-CH12 mAb
binding. CAP206-CH12_RUA also bound to gp41-inter but with
an even weaker Kd of 265 nM and koff (koff=1.1610
23 s21)
which was about 20-fold faster than that of the mature CAP206-
CH12 mAb (Figure 2D).
In contrast to 4E10, CAP206-CH12 and CAP206-CH12_RUA
binding to cardiolipin or PS containing liposomes was consider-
ably weaker (Figure 3A and 3B). Furthermore, CAP206-CH12
failed to bind to MPER656 peptide liposome complexes
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(MPER656) in the absence of lipids (Figure 1B), the lack of binding
of CAP206-CH12 to MPER peptide liposome complexes likely
reflects either its inability to interact with membrane embedded
critical residues or with the conformation of the MPER peptide on
liposomes with the net result that CAP206-CH12 mAb cannot
extract the MPER from lipid [19,20].
Like mAb 4E10, CAP206-CH12 was markedly polyreactive and
bound to histones, centromere B autoantigens and ribonucleo-
protein (Figure 4A). The RUA also reacted with SSA. In the Hep-
2 cell fluorescence assay, CAP206-CH12 did not react with Hep-2
epithelial cells while its RUA reacted in a nuclear and cytoplasmic
pattern (Figure 4B).
Neutralizing Activity of CAP206-CH12
The functional activity of mAb CAP206-CH12 was tested in the
TZM-bl pseudovirus neutralization assay using viruses against
which the CAP206 plasma was active. Of the 6 viruses tested, 4
Figure 1. Isolation of the MPR.03-specific mAb CAP206-CH12. (A) Flow cytometric plot of CD19+/CD27+ memory B cells from CAP206 stained
with labeled MPR.03 tetramers. Circled cells represent double-positive memory B cells that were single-cell sorted into 96-well plates for Ig gene
amplification and expression. B cells from HIV negative individuals did not stain with MPR.03 tetramers (not shown). (B) ELISA data showing binding
of CAP206-CH12 to MPR.03 peptide as well as MPER656 peptide. A scrambled MPR.03 peptide was negative as were peptides for the gp41
immunodominant (ID) region (SP400), 2F5 epitope (SP62 peptide) and 4E10 epitope. There was also no binding to JR-FL gp140, ConS gp140 or MN
trimeric gp41. Data from a single experiment representative of at least 3 is shown. (C) Binding of CAP206-CH12 to gp140 envelope proteins in
Western Blot. HIV-1 envelope proteins JR-FL gp140 (1), ConS gp140 (2) and the autologous protein, CAP206.B5.140C (3) were run under non-reducing
and reducing conditions. Western blots were stained with CAP206-CH12 at 2 mg/ml or with the 4E10 mAb as a positive control. Bound mAb was
detected using AP-labelled goat anti-human IgG.
doi:10.1371/journal.pone.0023532.g001
Table 1. CAP206-CH12 germ-line gene families compared to 4E10 and Z13e1.*
Antibody ID VH JH VL
Family CDR3 length % mutated Family Family CDR3 length % mutated
CAP206-CH12 1,69*04 17 11.9 6*03 3,20*01 11 5.2
4E10 1,69*10 20 12.6 1*01 3,20*01 9 7
Z13e1 4,59*03 19 17 6*03 3,11*01 9 3.5
*using SoDA algorithm.
doi:10.1371/journal.pone.0023532.t001
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included the autologous virus as well as 2 subtype C and 1 subtypeB
virus. CAP206-CH12 when tested at 32 mg/ml did not neutralize 2
other viruses against which the plasma showed low levels of activity.
Comparison of the IC50 values suggested that CAP206-CH12 was
similar in potency to the mAb Z13e1 and consistent with earlier
data using polyclonal antibodies eluted from MPR.03 peptides [15].
CAP206-CH12 was considerably less potent than mAb 4E10, but
more cross-reactive than 2F5 which generally fails to neutralize
subtypeC viruses[21]. When tested against a largeunselected panel
of primary Tier 2 viruses of subtypes A, B and C, CAP206-CH12
neutralized 2 of the 26 heterologous viruses; Du156.12 and
ZM197M.PB7 previously shown to be neutralized by this mAb,
in addition to the autologous virus (Table S1).
Interestingly when a subset of these viruses was tested using TZM-bl
cells in which the FcRcI receptor had been transfected, increased
potency and breadth of CAP206-CH12 was observed as has been
previously reported for mAb 4E10 (Table 3) [22]. Thus, there was a 2–
12 fold increase in sensitivity and two viruses (Du422.1 and
SC422661.8) that were previously resistant were now sensitive to
CAP206-CH12.
Mapping of MPER Residues Important for Neutralization
We used the subtype C pseudovirus, COT6.15 which has been
alanine-scanned across the MPER, to assess which residues were
crucial for neutralization. As shown in Table 4, the mutations
D674A, N677A and W680A had a major effect on neutralization
by CAP206-CH12 while F673A had a lesser effect. Two of these
residues (F673 and W680) are also crucial for 4E10 neutralization
and both F673 and D674 were previously shown to affect
neutralization by CAP206 plasma antibodies [15].
Analysis of MPER sequences of viruses sensitive to CAP206-
CH12 showed that all had an aspartic acid at position 674 similar
to the sequence present in the MPR.03 peptide (Figure S3). The
amino acid at position 677, the other site identified by alanine
substitution mapping as important for CAP206-CH12 neutraliza-
tion, was more variable with sensitive isolates tolerating K, N or H.
QH0692.42 was sensitive to plasma antibodies but not to
CAP206-CH12 and had the nominal D674 but had an arginine
at position 677 possibly accounting for its lack of sensitivity. Other
isolates that had D674 and either K or N at 677 were resistant
suggesting that simply having the nominal epitope was not
sufficient and other aspects such as exposure of the MPER are
likely important in determining CAP206-CH12 sensitivity. The 2
other residues F673 and W680 identified in the COT6.15 scanning
as important for neutralization (Table 4) were highly conserved
across all sensitive and resistance isolates. Sites shown to be
important for binding (W672,I 675 and T676) (Figure S2) were also
either highly conserved or did not distinguish between the sensitive
and resistant isolates.
Figure 2. Binding of CAP206-CH12 mAb and CAP206-CH12 RUA to gp41 MPER peptide and gp41-inter protein. (A) Surface plasmon
resonance binding Kd and rate constants for CAP206-CH12 and (B) CAP206-CH12_RUA to MPR.03 peptide. Biotinylated MPER peptide was anchored
to a streptavidin coated chip and antibodies were injected at varying concentrations (40 – 5 ug/mL and 100 – 20 ug/mL for CAP206-CH12 mAb and
RUA respectively) over the peptide surfaces. Binding of (C) CAP206-CH12 and (D) CAP206-CH12_RUA to gp41-inter protein showed that the RUA Kd
was an order of magnitude weaker. For gp41-inter binding, each mAb was captured to about 1000 RU on an anti-Fc antibody immobilized surface
(24). Varying concentrations (10–100 ug/mL) of gp41-inter protein was injected over the antibody captured surfaces. Data is representative of two
independent measurements and in a second experiment, the measured binding Kd was 15.1 nM and 137 nM for CAP-206-CH12 mAb and RUA
respectively.
doi:10.1371/journal.pone.0023532.g002
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In this study we demonstrate the power of prior epitope
mapping of plasma neutralizing antibodies that allowed for the
rationale design of an antigen-specific memory B cell receptor
ligand (bait). Furthermore, the use of single cell sorting with dual-
labeled ligands facilitated the efficient and specific selection of
relevant memory B cells. Remarkably, we saw utilization of the
same VH and VL families by this new MPER neutralizing mAb,
CAP206-CH12, as that used by the prototype MPER mAb 4E10.
Overall, this approach has significant potential for the discovery of
additional novel neutralizing anti-MPER mAbs from HIV-1
infected individuals, which will allow for further interrogation of
this important gp41 vaccine target.
While the CAP206-CH12 mAb neutralized approximately two-
thirds of the viruses sensitive to CAP206 plasma antibodies, this
mAb did not recapitulate all the plasma neutralizing activity. This
suggests that this type of antibody was responsible for a portion of
the breadth observed in plasma, and that full coverage would likely
be provided by additional mAbs, possibly somatic variants of
CAP206-CH12. Indeed the isolation of additional VH1-69 heavy
chains from this individual supported this notion, although this
could not be proven due to the inability to express them as
functional mAbs. Nonetheless, the CAP206-CH12 mAb epitope
directly overlapped the epitope of plasma antibodies confirming
that it comprised a component of plasma neutralizing activity.
Overall, CAP206-CH12 showed modest neutralization activity
and limited potency, similar to Z13e1, and reacted with both
subtype C and B viruses. While the CAP206-CH12 mAb was
polyreactive, unlike 2F5 and 4E10, CAP206-CH12 did not bind
lipids avidly. Since both 2F5 and 4E10 rely on lipid reactivity for
virion membrane binding in order to mediate neutralization
[19,23,24], one hypothesis is that the neutralization potency of
CAP206-CH12 may be limited by its minimal lipid reactivity
which is under investigation. However, neutralization breadth and
potency of CAP206-CH12 could be enhanced by engaging with
FcRcI receptors, similar to 4E10 and 2F5. This is a feature unique
to anti-MPER mAbs and may be related to the pre-positioning of
these mAbs during the transient fusion process [22].
It was striking that CAP206-CH12 utilized the VH1-69 and
Vk3-20 similar to the gp41 antibody, 4E10. Gorny and colleagues
have previously reported that non-neutralizing human antibodies
that bind to epitopes in the cluster II region of gp41 (N-terminal to
the MPER) frequently use a VH1-69 Ig heavy chain [25]. Other
gp41 antibodies, such as D5 [26] and HK20 that binds to the stalk
of gp41 [27] also utilize VH1-69. Another example of restricted
usage of VH1-69 has recently been reported following the isolation
of influenza broadly neutralizing antibodies to the stalk of
hemagglutinin [28]. VH1-69 antibodies are hydrophobic and
one hypothesis is that these antibodies are preferentially used for
regions of virus envelopes that are in close proximity to viral
membranes. Alternatively, Johnson and co-workers reported that
Figure 3. Binding of CAP206-CH12 with phospholipids and MPER peptide-liposomes. (A) CAP206-CH12 mAb bound weakly to both
cardiolipin (PC:CL 25:75) and (B) phosphatidylserine (PC:PS 25:75) liposomes. Binding of 4E10 mAb to both forms of lipids and the lack of binding of
the non-neutralizing gp41 MPER mAb 13H11 [40], as positive and negative controls respectively is also shown. The reactivity of CAP206-CH12_RUA to
cardiolipin was similar to that of CAP206-CH12 mAb binding. (C) CAP206-CH12 mAb did not bind to MPER peptide liposomes (using MPER656a-GTHI)
to which 4E10 mAb bound strongly. Binding of each mAb at 100 ug/mL to liposomes anchored on a hydrophobic L1 sensor chip was performed as
described earlier [19,40]. Data is representative of at least two independent measurements.
doi:10.1371/journal.pone.0023532.g003
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directly related to the VH1-69 copy number [29]. Thus, both host
and immunogen factors may give rise to preferential usage of VH1-
69 in anti-viral responses.
Another interesting finding was that both CAP206-CH12 and
another anti-MPER mAb, Z13e1 had the YYYYMD motif in
their CDRH3 as a result of a shared J allele. In the case of Z13e1,
three of the Tyr residues positioned at the base of CDRH3 make
contacts with the peptide [12] and thus CAP206-CH12 could
potentially utilize these Tyr residues in a similar manner. It is
notable that both 4E10 and Z13e1 have a flexible CDRH3 tip that
bends away from the bound antigen [12]. While the 4E10
CDRH3 apex is involved in both lipid binding and neutralization
[11], the flexibility of the Z13e1 CDRH3 tip could allow it to
engage the membrane–bound epitope [12]. CAP206-CH12, has a
slightly shorter CDRH3 and includes some flexible residues
adjacent to the Tyr motif but lacks hydrophobic residues W or F,
that are present in both the 4E10 and Z13e1 CDRH3 apex (4E10
– GWGWLG; Z13e1 – SGFLN). Since CAP206-CH12 did not
bind to MPER peptide liposomes, in which MPER C-terminus
hydrophobic residues are membrane immersed [19], it is likely
that CAP206-CH12 targets a different gp41 conformation,
possibly one in which the MPER is more solvent exposed.
The epitope of the CAP206-CH12 mAb overlapped that of
both 4E10 and Z13e1. The Z13e1 epitope spans residues
S668LWNWFDITN677 [30] while binding studies identified the
epitope of CAP206-CH12 to WF(N/D)IT, which does not include
residues N-terminus to W670. In particular, position 674 was
shown to be critical for both Z13e1 and CAP206-CH12. Residue
F673, a major determinant of the 4E10 epitope was also important
for the CAP206-CH12 mAb as shown in both binding and
neutralization studies. For MPER mAbs that bind to overlapping
residues, differences in both orientation and conformation of gp41
recognized by 4E10 and Z13e1 have been described [12,31].
Based on the mapping and neutralization mutagenesis data, it is
likely that CAP206-CH12 binds to a 4E10-favored W672/F673
accessible MPER conformation.
The lack of binding to denatured or plate bound JR-FL or
ConS gp140 and also to gp41 proteins suggests that the epitope
recognized by CAP206-CH12 is conformation sensitive. Even in
cases where the MPER sequences were identical, differences
elsewhere in gp41 and also within gp120 might affect gp120-gp41
interactions and the overall conformation of MPER accounting for
the lack of binding. Furthermore, while denaturing gp140 proteins
would expose the linear sequence, it does not preserve the
secondary structure which may account for some of the differences
seen between peptides and denatured proteins. However, like the
Figure 4. Polyspecificity of CAP206-CH12 and its RUA. (A)
Reactivity of both CAP206-CH12 and CAP206-CH12_RUA with autoan-
tigens. Both antibodies reacted with Histone and Centromere B.
CAP206-CH12 also reacted with RNP (Ribonucleoprotein), while
CAP206-CH12_RUA reacted with SSA (Ro/Sjogren syndrome autoanti-
gen). Other antigens tested but were not-reactive were dsDNA (double
stranded DNA), Jo 1 (histidyl-tRNA synthetase), Scl 70 (Scleroderma), Sm
(Smith antigen) and SSB (Sjogren syndrome antigen B). Experiment
shown is representative of three. (B) CAP206-CH12 did not react with
human HEp-2 epithelial cells while CAP206-CH12_RUA showed nuclear
and cytoplasmic reactivity (top panels). The 2F5 mAb reacted with a
diffuse cytoplasmic and nuclear pattern as previously reported [10]
while 17b (gp120 CD4i mAb) used as a negative control showed no
reactivity (bottom panels). Each antibody was used at 50 ug/mL and
each image is at 6400 magnification. Data is representative of three
individual experiments.
doi:10.1371/journal.pone.0023532.g004
Table 2. CAP206-CH12 mAb neutralization of viruses
sensitive to CAP206 plasma.
Pseudovirus Subtype ID50 IC50 (mg/ml)
CAP206
plasma
CAP206-
CH12 Z13e1 2F5 4E10
CAP206.B5* C 6,143 5.9 nd .25 0.1
ZM197M.PB7 C 256 13 30 .25 1.1
Du156.12 C 232 14.9 4.7 .25 0.2
TRO.11 B 212 17.5 13.3 .25 0.3
QHO692.42 B 125 .32 46 1.81 6.5
Du422.1 C 90 .32 nd .25 0.3
Values are either the reciprocal plasma dilution (ID50) or mAb concentration
(IC50, mg/ml) at which relative luminescence units (RLUs) were reduced 50% in
TZM-bl cells compared to virus control wells (no test sample).
*indicates the autologous transmitted/founder virus.
doi:10.1371/journal.pone.0023532.t002
Table 3. Enhancement of CAP206-CH12 neutralization in
TZM-bl cells expressing FcRc1.
Pseudovirus Subtype IC50 (mg/ml)
CAP206-CH12 2F5 4E10
ZM197M.PB7 C 0.3 0.06 ,0.01
SC422661.8 B 0.4 ,0.01 ,0.01
Du156.12 C 0.6 .25 ,0.01
CAP206.B5* C 0.7 .25 ,0.01
Du422.1 C 2.7 .25 ,0.01
QH0692.42 B .32 ,0.01 0.11
Values are mAb concentration (IC50, mg/ml) at which relative luminescence units
(RLUs) were reduced 50% compared to virus control wells (no test sample).
*indicates the autologous transmitted/founder virus.
doi:10.1371/journal.pone.0023532.t003
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(2F5 and 4E10), CAP206-CH12 bound to gp41-inter protein.
Thus CAP206-CH12 is capable of targeting the pre-hairpin
intermediate conformation of gp41, which is not recognized by
non-neutralizing gp41 cluster II antibodies [18,32]. However, the
relatively weaker binding Kd of CAP206-CH12 for gp41-inter
protein is consistent with its poorer neutralization activity. Both
lipid reactivity and a stable binding of MPER antibodies with
extremely slow off-rates have been proposed to be a requirement
for the capture of the transient pre-hairpin intermediate
conformation and subsequently the blocking of cell fusion
[11,18]. CAP206-CH12 mAb, with its weaker reactivity and
relatively faster off-rates will therefore, be less efficient in capturing
the transient intermediate state of gp41. The even weaker binding
of CAP206-CH12_RUA to gp41-inter suggests that enhancement
in gp41-inter binding is acquired during maturation of the
antibody.
The finding that the germline-like antibody of CAP206-CH12
bound the MPR.03 peptide and gp41-inter weakly allows us to
propose a model whereby MPER epitopes on the early transmitted
founder virions initiated the hypermutation process in a naive B
cell during acute HIV-1 infection. The fact that the first binding
antibodies in HIV-1 infection are to gp41 [33], suggests that
CAP206-CH12 may be derived from one of the earliest B cell
precursors that encountered HIV. Initially these antibodies were
non-neutralizing but through a process of affinity maturation
acquired limited neutralization capacity. The polyreactivity of the
germline antibody may also have played a role in its maturation
which may be a common feature of antibodies targeting gp41
[34,35]. The mutation rate of the heavy chain of CAP206-CH12
while lower than that of other MPER neutralizing mAbs was
roughly similar to what is seen among other broadly neutralizing
mAbs [36,37]. It is possible that CAP206-CH12 represents an
intermediate in the maturation process of this clonotype. Further
work aims to examine the ontogeny of this antibody specificity to
explore this hypothesis.
Finally, our studies show that epitope mapping of plasma
antibodies followed by the rational design of fluoresceinated
MPER peptide tetramers can successfully isolate antigen-reactive
single B cells for Ig rescue. Scheid and colleagues have previously
used fluoresceinated gp140 envelope for this purpose for isolation
of Env-reactive B cells [5] and more recently VRC01 a potent
anti-CD4bs mAb was isolated using a modified gp120 protein [6].
Our strategy combined an antigen-specific probe with two color
labeling to increase sensitivity and enhance the specificity of
isolated antibodies. The methods used here should allow for the
isolation of broadly neutralizing antibodies from many subjects
with neutralizing antibody breadth where suitable antigens can be
designed. Study of the B cells and their reverted unmutated
ancestors should prove useful in design of immunogens capable of
activating B cell receptors of naı ¨ve cells that are able to develop
into anti-HIV-1 antibodies with neutralizing breadth.
Materials and Methods
Human Samples and Ethics Statement
Stored plasma and PBMC from CAP206 an HIV-1 subtype C
chronically infected individual were used for this study. This
participant was part of the CAPRISA 002 Acute infection cohort
whose antibody neutralization profile has been studied since the
point of seroconversion [13,38]. This study was approved by the
IRB’s of the Universities of KwaZulu Natal and Witwatersrand in
South Africa and Duke University. Written informed consent was
obtained from all study participants.
Reagents
The MPR.03 biotinylated peptide containing lysines at both
ends for solubility (KKKNEQELLELDKWASLWNWFDITN
WLWYIRKKK-biotin) and a scrambled version were purchased
from CPC Scientific Inc (San Jose, CA). Peptides were .98% pure
as tested by HPLC. MPER656 (Biotin-NEQELLELDK-
WASLWNWFNITNWLW), SP62 (2F5 peptide), SP400 (peptide
from gp41 immunodominant region) and 4E10 peptides have been
described previously [39]. The MPER656a-GTH1 peptide
(NEQELLELDKWASLWNWFNITNWLWYIK-YKR-
WIILGLNKIVRMYS) was used in the preparation of MPER
peptide liposomes [19,40]. Proteins ConS gp140, JR-FL gp140
were generated as described [41] and MN gp41 was purchased
Table 4. MPER amino acid residues critical for CAP206-CH12 neutralization.
COT6.15 CAP206-CH12 mAb CAP206 plasma 4E10 mAb
MPER mutants IC50 ratio to WT ID50 ratio to WT IC50 ratio to WT
Wild-Type (WT) 11.0 1.0 1,256 1.0 0.9 1.0
W670A 4.1 0.4 1,054 1.2 0.1 0.1
S671A 2.6 0.2 1,614 0.8 0.0 0.0
W672A 1.1 0.1 2,244 0.6 .25 .25
F673A 23 2.1 498 2.5 .25 .25
D674A 150 13.7 ,50 .25 1.4 1.6
I675A 14.6 1.3 2,065 0.6 0.0 0.0
T676A 15.4 1.4 895 1.4 21.8 24.2
K677A 150 13.7 2,151 0.6 0.1 0.1
W678A 1.8 0.2 1,885 0.7 0.1 0.1
L679A 1.7 0.2 1,448 0.9 0.1 0.1
W680A 150 13.7 904 1.4 10.9 12.1
Values are either the mAb concentration (IC50, mg/ml) or reciprocal plasma dilution (ID50) at which relative luminescence units (RLUs) were reduced 50% compared to
wild-type COT6.15 virus.
doi:10.1371/journal.pone.0023532.t004
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were obtained from Polymun, Vienna, Austria. The CAP206.B5
virus was cloned by SGA from a pre-seroconversion plasma
sample and is the autologous transmitted founder virus. A gp140
protein, CAP206.B5.140C with the gp120-gp41 cleavage site
mutated (REKR motif), was used in Western blots and ELISA’s.
Other viruses were from the standard clade A, B and C reference
panels [42,43,44]. MPER mutants made in the subtype C virus,
COT6.15 have been described previously [15]. HIVIG-C is a pool
of purified IgG from five blood bank donors in Johannesburg,
South Africa who were confirmed by sequence analysis to be
infected with subtype C HIV-1.
Preparation of Tetramers
Tetramers were prepared using the biotinylated MPR.03 peptide
with both allophycocyanin (APC) and Pacific Blue labelled
streptavidins and titered on antibody-coated beads and on antibody
expressing cell lines (using the 13H11 and 2F5 mAbs which both
bind the MPR.03 peptide). Briefly, excess biotinylated peptide
(approximately 33:1 molar ratio of peptide to streptavidin for
fluorochrome-labeledtetramers)wasincubatedat4uCovernightand
isolated using gel filtration on Micro BioSpin 30 columns. Tetramers
were assayed for final concentration determined using standard
spectrophotometric techniques. Final titers were determined using a
combination of 2F5-coated beads and 13H11- expressing cell lines.
Tetramers were used in equimolar amounts in combination with a
panel of mAbs to identify memory B cells in PBMC.
Staining and Sorting B Cell Populations
Thawed PBMC were stained with a combination of the
following antibodies: CD3 PE-Cy5, CD14 PE-Cy5, CD16 PE-
Cy5, CD235a PE-Cy5, CD19 APC-Cy7, CD27 PE-Cy7, CD38
APC-Cy5.5 and IgG-PE (BD Biosciences, Mountain View, CA
and Invitrogen, Carlsbad, CA). All antibodies were titered and
used at optimal concentrations for flow cytometry. Memory B cells
were gated as CD3
neg, CD14
neg, CD16
neg, CD235a
neg, CD19
pos,
CD27
hi, CD38l
ow and IgG
+. Tetramer-stained B cells were sorted
as single cells into wells of a 96-well plate, selecting those cells that
were labelled by both tetramers. Cells were stored in reverse-
transcriptase reaction buffer at 280uC until use [45]. Flow
cytometric data was acquired on a BD FACS Aria and the data
analyzed using FlowJo.
Isolation of Ig Variable Gene Transcripts
The genes encoding VH and VL were amplified by PCR using a
modification of the method described by Tiller and co-workers
[46]. Briefly RNA from single sorted cells was reverse transcribed
using Superscript III in the presence of primers specific for human
IgG, IgM, IgD, IgA1, IgA2, kappa and lambda constant gene
regions [45]. The VH,V K and VL genes were amplified from this
cDNA separately in a 96-well nested PCR as described and
analysed on 2% agarose gels [45]. The second round PCR
included tagged primer sequences at the 59 end which permitted
assembling of the VH and VL genes into functional linear Ig gene
expression cassettes (see below). PCR products were purified and
sequenced. The variable gene segments and the potential
functionality of the Ig genes was determined using the SoDA
program [47].
Expression of Recombinant Antibodies from Linear
Expression Cassettes
Three linear Ig expression cassettes each containing the CMV
promoter and human Ig leader as one fragment were used for
small-scale expression and specificity analysis [45]. Fragments for
the heavy and light chains comprised either the IgG1 constant
region, Ig kappa constant region or Ig lambda constant region
attached to poly A signal sequences. These two fragments plus
either VH,V K or VL genes amplified from single B cells were
assembled by overlapping PCR. PCR products containing linear
full-length Ig heavy- and light-chain genes were purified and the
paired Ig heavy and light-chain products co-transfected into 293T
cells grown in 12-well plates using Fugene. Cultures were fed 6–
12 hrs later with ,2 mls fresh medium containing 2% FCS and
incubated for 72 hours at 37uC in a 5% CO2 incubator.
Thereafter culture supernatants were harvested for antibody
characterization.
Design and Synthesis of CAP206-CH12 Inferred Reverted
Unmutated Ancestor
The SoDA program [47] was used to infer the reverted
unmutated ancestor (RUA) of CAP206-CH12. These genes were
synthesized (GeneScript, Piscataway, NJ) and cloned as full-length
IgG1 for heavy chain and full-length kappa light chain genes into
pcDNA3.1 plasmid (Invitrogen; Carlsbad, CA) using standard
recombinant techniques.
Production of Purified Recombinant MAbs
The selected Ig VH and VK genes from CAP206-CH12 were
cloned into human Igc and Igk expression vectors in pcDNA3.3
[45]. Clones with the correct size inserts were sequenced to
confirm identity with the original PCR products. For production
of purified antibodies of CAP206-CH12 and CAP206-
CH12_RUA by batch transient transfections, 10–20 T-175 flasks
of 293T cells grown at 80–90% confluency in serum-free media
were co-transfected with plasmids expressing HIV-1 specific Ig
heavy- and light chain genes using Fugene (Qiagen, Valencia,
CA). Recombinant antibodies were purified using anti-human IgG
heavy-chain specific antibody-agarose columns.
ELISA and Western blots
Supernatants from the small scale transfections and purified
mAbs were tested for reactivity using various peptides and proteins
in an ELISA as described [45]. An anti-cardiolipin ELISA was
used as previously described [48,49]. Autoantibodies were
measured by the FDA-approved AtheNA Multi-LyteH ANA II
Test Kit from Zeus Scientific, Inc. per the manufacturer’s
instructions and as described previously [10]. Western blots were
performed using NuPAGEH Novex 4–12% Bis-Tris gels, 1.0 mg
per lane for coomassie blue stain and 0.5 mg per lane for Western
blot. Gels were run at 200 V for 50 min under non-reducing and
reducing conditions. The coomassie images were acquired in
Odyssey Infrared Imaging System (Li Cor Bioscience, Lincoln,
NE). Alkaline-phosphatase conjugated goat anti-human IgG
(Sigma, St. Louis, MO) at 1:5000 dilution was applied as
secondary Ab. The membranes were developed in Western BlueH
Stabilized Substrate (Promega, Madison, WI).
Surface Plasmon Resonance
MPER656, MPR.03 and a scrambled version of MPR.03 were
individually anchored on a BIAcore SA sensor chip as described
previously [40,50]. Binding assays were performed on a BIAcore
3000 instrument at 25uC and data analyzed using the BIAevalua-
tion 4.1 software (BIAcore) [40]. Peptides were injected until 100–
150 response units of binding to streptavidin were observed.
Trimeric 92UG gp41-inter protein was produced and purified as
described earlier [18]. Antibodies were captured on an anti-
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of gp41-inter protein was injected over the antibody surfaces.
Binding Kd measurements were made as described earlier
[18,19,39,40].
Neutralization Assays
The TZM-bl pseudovirus assay was used to assess the
neutralization activity of CAP206-CH12 and control mAbs
against viruses that were sensitive to CAP206 plasma antibodies
as well as to a large panel of 26 unselected heterologous Tier 2
viruses from multiple subtypes available in Dr David Montefiori’s
CAVD Consortium. Mapping of residues in the MPER crucial for
CAP206-CH12 neutralization made use of the COT6.15 virus
which was alanine-scanned across the MPER. The mAb
concentration at which 50% of virus neutralization was seen
(IC50 value) was reported. Purified mAb was used for these
experiments to avoid interference from transfection reagents.
Plasma was heat inactivated prior to performing neutralization
assays.
Supporting Information
Figure S1 Amino acid alignment of CAP206-CH12 VH
and VL chains with 4E10 and Z13e1 (A) and nucleotide
sequences of CAP206-CH12 and CAP206-CH12_RUA
heavy and light chains (B).
(PPTX)
Figure S2 Mapping of a MPER amino acid residues
important for CAP206-CH12 and 4E10 binding. Bargraphs
show relative binding of CAP206-CH12 and 4E10 mAbs to alanine
scanned MPER656 peptides. Residues highlighted in red show
more than 50% reduction in binding relative to wild-type peptide.
Individual SPR curves for 3 residues W672,F 673,N 674 (boxed in bar
graph) normalized to 100% binding show the differential effect of
the substitution on 4E10 (blue) and CAP206-CH12 (red) binding.
While each of the substitutions drastically reduced the binding
(.50%) of CAP206-CH12 relative to wild-type, the substitutions
show marked differences in the off-rates of the binding of 4E10 to
W672A and F673A peptides but not to N674A. Thus W672A and
F673A substitutions had a more drastic effect on 4E10 binding than
CAP206-CH12 binding.Alanine substituted mutantsweredesigned
by substituting single amino acids within the MPER peptide with
the following sequence – Biotin-GGG-QELLELDKWASLWNWF
NITNWLWYIK (MPER26). Relative binding of the mutants was
measured using the wild type MPER656 peptide (Biotin-NEQEL-
LELDKWASLWNWFNITNWLW). The binding of CAP206-
CH12 mAb to all three MPER peptides (MPR.03, MPER656,
MPER26) used in this study were similar. CAP206-CH12 bound to
MPER26 and MPER656 peptide with Kd of 4.95 and 5.15 nM
respectively.
(PDF)
Figure S3 MPER sequences of viruses sensitive and
resistant to CAP206-CH12 mAb. Amino acids at positions
674 and 677 are highlighted in red. Residues at 673 and 680
(boxed) were conserved in all sensitive and resistant isolates.
(PDF)
Table S1 Neutralization sensitivity of viruses to
CAP206-CH12.
(PDF)
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